Q-omics provides the consensus-scored INHBB profile across patient tissues and cancer cell-line models. INHBB expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, INHBB is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, INHBB RNA expression shows 16,431 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, KIRC, and THYM as cancer lineages where INHBB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INHBB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INHBB survival associations across molecular data types. INHBB RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INHBB RNA expression–survival associations across cancer types. High INHBB expression shows unfavorable associations in COAD, UVM, KIRP, STAD and HNSC, but favorable associations in THCA. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for INHBB RNA expression.
This table summarizes INHBB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for INHBB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INHBB shows lower tumor expression in BRCA and BLCA and higher tumor expression in KIRC, COAD, THCA and KIRP. The KIRC box plot shows higher INHBB RNA expression in tumor versus normal tissue (log2 FC = +3.889, t-test p < 0.001).
This table shows molecular features associated with INHBB in patient tissues and cancer cell lines. In patient samples, INHBB shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, INHBB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BONE.
